Advertisement

Myelodysplastische Syndrome

  • Franziska La Meir
  • Tobias Boch
  • Daniel Nowak
  • Georgia Metzgeroth
  • Wolf-Karsten Hofmann
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die Myelodysplastischen Syndrome (MDS) sind eine heterogene Gruppe erworbener klonaler Erkrankungen des Knochenmarks. Sie sind mit einem medianen Manifestationsalter zwischen 70 und 80 Jahren vorwiegend eine Erkrankung des älteren Menschen. Ein MDS tritt zumeist primär ohne erkennbaren Grund oder in Folge einer Exposition gegenüber Chemotherapeutika, Strahlen oder anderen Noxen (z. B. Benzol) auf. Klinisch manifestiert sich das MDS durch ein fortschreitendes Knochenmarkversagen bei ineffektiver Hämatopoese mit peripherer Zytopenie und einem Risiko für eine Transformation in eine akute myeloische Leukämie (AML). Die Prognose und das Risiko für eine Transformation in eine AML werden vor allem durch den Blastenanteil und molekulargenetische bzw. zytogenetische Aberrationen bestimmt. Die therapeutischen Strategien umfassen reine Supportivmaßnahmen, Therapien mit immunmodulatorischen Substanzen, demethylierende Substanzen sowie die allogene Stammzelltransplantation als einzige kurative Therapie.

Literatur

  1. Ades L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet 383:2239–2252CrossRefPubMedGoogle Scholar
  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMedGoogle Scholar
  3. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506CrossRefPubMedPubMedCentralGoogle Scholar
  4. Burgstaller S, Wiesinger P, Stauder R (2015) Myelodysplastic syndromes in the elderly: treatment options and personalized management. Drugs Aging 32:891–905CrossRefPubMedGoogle Scholar
  5. Cogle CR (2015) Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep 10:272–281CrossRefPubMedPubMedCentralGoogle Scholar
  6. Fain O, Braun T, Stirnemann J, Fenaux P (2011) Systemic and autoimmune manifestations in myelodysplastic syndromes. Rev Med Interne 32(9):552–559.  https://doi.org/10.1016/j.revmed.2010.08.005, Epub 20.09.2010CrossRefPubMedGoogle Scholar
  7. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Canizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lubbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellstrom-Lindberg E, M. D. S. Lenalidomide del5q Study Group (2011) A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:3765–3776CrossRefPubMedGoogle Scholar
  8. Gangat N, Patnaik MM, Tefferi A (2016) Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol 91:76–89CrossRefPubMedGoogle Scholar
  9. Garcia-Manero G (2015) Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol 90:831–841CrossRefPubMedGoogle Scholar
  10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  11. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRefPubMedPubMedCentralGoogle Scholar
  12. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247CrossRefPubMedGoogle Scholar
  13. Heuser M, Thol F, Ganser A (2016) Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int 113:317–322PubMedPubMedCentralGoogle Scholar
  14. Klepin HD, Rao AV, Pardee TS (2014) Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol 32:2541–2552CrossRefPubMedPubMedCentralGoogle Scholar
  15. Kronke J, Hurst SN, Ebert BL (2014) Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology 3, e941742CrossRefPubMedPubMedCentralGoogle Scholar
  16. Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U, M. D. S. with del International Working Group on (2013) Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 27:1072–1079CrossRefPubMedPubMedCentralGoogle Scholar
  17. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, Kroger N, Mufti GJ, De Witte TM (2010) Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28:405–411CrossRefPubMedGoogle Scholar
  18. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557CrossRefPubMedGoogle Scholar
  19. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pfluger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987–1996CrossRefPubMedGoogle Scholar
  20. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M, Leukemia NE (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943–2964CrossRefPubMedPubMedCentralGoogle Scholar
  21. Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, Mudder K, Klein C, Oblander J, Fey S, Vogler J, Fabarius A, Riedl E, Roehl H, Kohlmann A, Staller M, Haferlach C, Muller N, John T, Platzbecker U, Metzgeroth G, Hofmann WK, Trumpp A, Nowak D (2014) Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14:824–837CrossRefPubMedGoogle Scholar
  22. Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Oblander J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Rohl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelss P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D (2016) Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 128:1246–1259CrossRefPubMedGoogle Scholar
  23. Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2012) Improved survival in MDS patients receiving iron chelation therapy – a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36:1067–1070CrossRefPubMedGoogle Scholar
  24. Nolte F, Hochsmann B, Giagounidis A, Lubbert M, Platzbecker U, Haase D, Luck A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H (2013) Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 92:191–198CrossRefPubMedGoogle Scholar
  25. Oran B (2015) Which patients should undergo allogeneic stem cell transplantation for myelodysplastic syndromes, and when should we do it? Clin Lymphoma Myeloma Leuk 15 Suppl:S43–S49CrossRefPubMedGoogle Scholar
  26. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O’Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ, Consortium Chronic Myeloid Disorders Working Group of the International Cancer Genome (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616–3627; quiz 99CrossRefPubMedPubMedCentralGoogle Scholar
  27. Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang AS, Fenaux P (2014) Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia 28:2418–2421CrossRefPubMedPubMedCentralGoogle Scholar
  28. Pleyer L, Greil R (2015) Digging deep into „dirty“ drugs – modulation of the methylation machinery. Drug Metab Rev 47:252–279CrossRefPubMedPubMedCentralGoogle Scholar
  29. Quintas-Cardama A, Santos FP, Garcia-Manero G (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25:226–235CrossRefPubMedGoogle Scholar
  30. Raaijmakers MH (2010) Regulating traffic in the hematopoietic stem cell niche. Haematologica 95:1439–1441CrossRefPubMedPubMedCentralGoogle Scholar
  31. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829CrossRefPubMedPubMedCentralGoogle Scholar
  32. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16CrossRefPubMedPubMedCentralGoogle Scholar
  33. Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R (2014) Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20:408–414CrossRefPubMedGoogle Scholar
  34. Talati C, Griffiths EA, Wetzler M, Wang ES (2016) Polo-like kinase inhibitors in hematologic malignancies. Crit Rev Oncol Hematol 98:200–210CrossRefPubMedGoogle Scholar
  35. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE (2007) A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129:1097–1110CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Franziska La Meir
    • 1
  • Tobias Boch
    • 1
  • Daniel Nowak
    • 1
  • Georgia Metzgeroth
    • 1
  • Wolf-Karsten Hofmann
    • 1
  1. 1.III. Medizinische Klinik, Hämatologie/OnkologieUniversitätsmedizin Mannheim der Universität HeidelbergMannheimDeutschland

Section editors and affiliations

  • Ulrich Wedding
    • 1
  1. 1.Abteilung für PalliativmedizinUniversitätsklinikum Jena, Klinik für Innere Medizin IIJenaDeutschland

Personalised recommendations